daratumumab injection

daratumumab injection
for intravenous use Initial U.S. Approval

Darzalex (daratumumab) is a human CD38-directed monoclonal antibody used to treat multiple myeloma.

Facts about daratumumab injection

DISEASE INDICATIONS-Multiple Myeloma
MANUFACTURER-Janssen-Cilag International N.V.
USAGE-Intravenous
MEDICINE APPROVED BY-European Medical Agency (EMA),Food and Drug Administration (FDA),Health Canada,Therapeutic Goods Administration (TGA),Medsafe (NZ)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “daratumumab injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

Contact Info

CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398

EMAIL ID:
info@indianpharmanetwork.co.in

FAX NUMBER:
+91-11-26532129

Query For daratumumab injection

Description

Approved accessible "daratumumab injection"

DARZALEX is a CD38-directed cytolytic antibody indicated:

in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent.
In November 2015, the U.S. Food and Drug Administration (FDA) approved daratumumab for treatment of multiple myeloma in patients who had received at least three prior therapies. In May 2016 daratumumab was also conditionally approved by the European Medicines Agency for treatment of multiple myeloma.
In November 2016, the FDA approved daratumumab in combination with lenalidomide or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
In May 2018, the FDA expanded the approval of daratumumab for use in combination with bortezomib, melphalan and prednisone to include the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

How can 1 go about obtaining daratumumab injection?

If daratumumab injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

DARZALEX (daratumumab) injection, for intravenous use Initial U.S. Approval: 2015

References

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398

Free Customer Support
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in

daratumumab injection